Brief: Curevac Announces Dosing Of First Participant In Combined Phase 1/2 Study Of Multivalent, Modified Influenza Vaccine Candidates
08/05/2023 12:02
May 8 (Reuters) - Curevac Nv 5CV.DE :
* EQS-NEWS: CUREVAC ANNOUNCES DOSING OF FIRST PARTICIPANT IN
COMBINED PHASE 1/2 STUDY OF MULTIVALENT, MODIFIED INFLUENZA
VACCINE CANDIDATES DEVELOPED IN COLLABORATION WITH GSK
* TESTED MULTIVALENT VACCINE CANDIDATES ADDRESS ALL FOUR
WHO-RECOMMENDED FLU STRAINS
Source text for Eikon: ID:nEQ8rn0Hha
Further company coverage: 5CV.DE
((frankfurt.newsroom@thomsonreuters.com;))
Recent news on CureVac NV
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Biontech Closes Acquisition Of CureVac
Brief: BioNTech Says CureVac Shareholders Are Advised To Tender Their Shares By 6:00 P.M. Eastern Time On Tuesday, December 2, 2025
Brief: Curevac Reaffirms Its Expected Cash Runway Into 2028